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chromosome, in the vicinity of the genes for MAOA and fnonoamine oxidase B (MAOB). Because MAOA and MAOB are known to metabolize serotonin, dopamine, and noradrenaline, we evaluated these patients for MAO deficiency. The MAOB activity is normal in affected males from this family (13) .
To test the hypothesis that affected males in this family have selective MAOA deficiency, we established skin fibroblast cultures from three clinically affected males, two carrier females, and one noncarrier female (14). Cultured human skin fibroblasts from normal individuals express both MAOA and MAOB activity in a ratio of about 80 to 90% to 10 to 20%, respectively, and the amounts of actieity are stable from passage to passage during the proliferative growth phase (15). Treatment of fibroblast cultures with dexamethasone produces a 6-to 14-fold increase in MAOA activity and a 2-to 3-fold increase in MAOB activity (16 18) . These controls were grown in parallel with fibroblasts from family members to minimize activity differences due to serum components (19). Negligible amounts of apparent MAO activity were found in strains from three affected males in the presence or absence of dexamethasone ( Table 1 ). The amounts of activity in two carrier females and in one noncarrier female from the same family were in the low to moderate control range and, as in control strains, were increased by treatment with dexamethasone and inhibited by more than 90% by the selective MAOA inhibitor, clorgyline.
To establish whether the lack of MAOA activity was caused by a mutation in the MAOA structural gene, we determined the coding sequence of the mRNA for MAOA by first-strand complementary DNA (cDNA) synthesis, polymerase chain reaction (PCR) amplification, and direct sequencing (20). Four base substitutions were detected, three of which were neutral polymorphisms (G to T at position 941, T to A at position 1077, and T to C at position 1460). However, a nonconservative C to T mutation was found at position 936. This mutation changes a glutamine (CAG) codon to a termination (TAG) codon at position 296 of the deduced amino acid sequence (21) (Fig. 1) . Amplification and sequencing of the eighth exon (22), which contains nucleotides 846 to 1005, confirmed the presence of the C to T mutation at nucleotide 936 in each of five clinically affected males and in two obligatory heterozygotes. In contrast, the mutation could be excluded in 12 unaffected males in this family (Fig. 1) 
